ProCE Banner Series

Don’t Delay: Prompt Diagnosis and Emerging Treatment Strategies for Acromegaly

Join us to learn about updates in managing acromegaly, including best practices in early recognition and diagnosis, the latest available evidence and emerging treatment options, and strategies for individualizing care to optimize outcomes.

  AAPA
  | AMA
  | ANCC
Who Should Attend

This program is intended for endocrinologists, endocrinology fellows, and endocrinology nurse practitioners and physician associates.

All Events

Don’t Delay: Prompt Diagnosis and Emerging Treatment Strategies for Acromegaly

Upcoming Events

July

23

2024

6:00 PM - 7:00 PM Pacific Time (PT)

Virtual

September

19

2024

7:00 PM - 8:00 PM Eastern Time (ET)

Virtual

Past Events

April

10

2024

7:00 PM - 8:00 PM Central Time (CT)

Virtual

Faculty

ProCE Banner Faculty
Julie M. Silverstein, MD

Medical Director Pituitary Center
Director, Clinical Trials Unit
Associate Professor of Medicine and Neurological Surgery
Division of Endocrinology, Metabolism and Lipid Research
Washington University School of Medicine
St. Louis, Missouri

Topics

Acromegaly

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with acromegaly. 

Target Audience
This program is intended for endocrinologists, endocrinology fellows, and endocrinology nurse practitioners, and physician associates.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Implement strategies that emphasize recognizing risk factors and early screening for acromegaly to reduce diagnostic delays
  • Select appropriate pharmacotherapy for long term management of acromegaly based on clinical evidence, including the latest efficacy and safety data
  • Incorporate guideline recommendations and evidence-based therapies into individualized treatment plans for patients with acromegaly

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.

Physician Associate Continuing Medical Education

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim commensurate with the extent of their participation.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by educational grants from Chiesi USA and Recordati Rare Diseases.